29 / 62
TMZ/Veliparib
Placebo/TMZ
Veliparib/TMZ
SLFN11-positive tumors
(p=0.01)
Progression Free Survival
Months
SLFN11+ (Veliparib/TMZ, n=14)
SLFN11+ (Placebo/TMZ, n=11)
SLFN11 positive = H-score ≥1
PFS
OS
Pietanza, Byers et al.,
WCLC
2016
SLFN11 protein expression (IHC) might predict
benefit from PARP inhibition